We have explored the effect of antiretroviral drugs on the antiviral immune response in human immunodeficiency virus-1 (HIV-1)-infected patients by using an enzymatic immunosensor that detects epitope-modifying anti-gp41 antibodies. By this molecular sensing approach, we have identified an irreversible impact of drug administration on the functionality of IgG4 and IgM specific antibodies regarding the structural modification promoted on their target epitope. During the antiretroviral therapy, the prevalent induced fit promoted by IgM on the epitope was lost at the expense of that promoted by IgG4, suggesting alternativeness in the neutralization potency of these antibody subpopulations. Because the particular drug composition of the antiretroviral treatment did not affect such immune shift, the obtained data strongly suggest that the drop in the viral load and the consequent lost of antigenemia are responsible for the functional adaptation observed in the humoral response. (Journal of Biomolecular Screening 2008:817-821) 
INTRODUCTION
T HE HUMORAL RESPONSE against the human immunodeficiency virus-1 (hiv-1) infection has long been considered of poor relevance regarding the progression of the infection. However, antibody-mediated viral neutralization and the consequent rising of evasive mutants have been proven as important contributors of HIV-1 dynamics in infected individuals. 1, 2 In the case of HIV-1, the neutralization potency of antiviral antibodies directed to env gene products (gp41 and gp120) depends on the extent of structural perturbations caused by the antibody binding on the target epitope and surrounding areas. 3, 4 This fact might be related to the high conformational flexibility of gp41-gp120 complexes at the virion surface that is required for the structural adaptation of both proteins to the CD4 receptor during cell attachment. 5 The neutralization potency of selected monoclonal antibodies can be predicted through monitoring the enthalpic and entropic changes in the ligand upon antibody binding as a reflection of the extent of induced fit. 3 However, such parameters cannot be obtained from whole sera, and the spectrum of available neutralization assays remains as the only suitable method for evaluation of neutralization capability. 6 On the other hand, it is known that HIV-1 replication is required for an efficient production and maintenance of significant titers of anti-HIV-1 immunoglobulin (Ig)G antibodies in serum. 7 Consequently, the administration of antiretroviral therapy (ART) has a dramatic, negative impact on the immunoglobulin titer in treated subjects. 7, 8 However, there are no data about how ART can modify the functional quality of antiviral antibodies, and how the inhibition of viral replication might affect the neutralization potential and functional distribution among different antiviral antibody subpopulations.
With the aim to determine any eventual functional modification that ART might induce in the antiviral response, we have here examined the capability of different Ig classes to activate the allosteric molecular sensor NF795gpC, in sera from both untreated and treated patients.
NF795gpC is an engineered version of the Escherichia coli β-galactosidase that displays the main immunodominant epitope from HIV-1 gp41 in a solvent-exposed area of the protein. 9 This hybrid protein responds allosterically to anti-gp41 monoclonal and polyclonal antibodies through conformational perturbations induced by the antibody on the enzyme's active site. Therefore, apart from being a very efficient and sensitive "protein-only" biosensor 9 for the detection of HIV-1 infection, 10 the conformational sensitivity of NF795gpC makes this enzyme a useful tool to evaluate the "induced fit" abilities of specific anti-HIV-1 antibody populations. 11
MATERIALS AND METHODS

Biosensor description and production
The antibody-sensing β-galactosidase enzyme NF795gpC displays the P1 immunodominant B-cell epitope of HIV-1 gp41 in a solvent-exposed position. 9 In this location, the accommodated viral peptide is accessible and fully immunoreactive. The binding of specific anti-P1 antibodies produces structural changes that result in detectable variations in the enzyme specific activity, easily detectable in a homogeneous assay. The hybrid enzyme NF795gpC becomes then an allosteric nanosensor 10 in which the P1 peptide acts as the specific receptor and antibodies as allosteric effectors. NF795gpC was produced in E. coli BL26 strain through the thermosensitive expression vector pNF795gpC. After 4 h of induction at 42 °C, protein was centrifuged and purified by conventional affinity chromatography. 11 The harvested protein was then dialyzed against Z buffer, 12 and it was quantified by Bradford analysis. 13
Sera samples
A total of 57 HIV-1-infected human sera were used in this study ( Table 1) . Eighteen were from healthy individuals, 20 from HIV-1-infected patients who received ART without interruption for 55 weeks (mean; range 16-120), and 19 from HIV-1-infected patients who underwent structured treatment interruption for 30 weeks (mean; range 2-112 weeks). All the sera were tested for NF795gpC allosteric activation. Sera from 8 noninfected individuals were included in the analysis as negative controls.
Biosensing analysis
The enzymatic sensing assay was performed in 96-well microplates by incubating 20 μl of 1:4 dilution of each serum in Z buffer (pH 7.0; 0.06 M Na 2 HPO 4 , 0.04 M NaH 2 PO 4 H 2 O, 0.01 M KCl, 1 mM MgSO4 7H 2 O) with 10 μl of 4.16 nM NF795gpC per well. After incubation for 1 h at 25 °C, 40 μl of 1.66 mM chlorophenol red β-D-galactopyranoside (CPRG, a lactose analogue rendering red hydrolysis products) in Z buffer were added. After 30 min of reaction, the absorbance was determined at 540 nm in a Labsystems iEMS plate reader. Percentages of enzyme activation were determined by referring to values obtained in absence of sera and used as a convenient numeric biosensing signal. All the experiments were performed in triplicate.
ELISA
For antibody class and subclass analyses, high binding Costar ELISA plates were coated with saturating concentrations of NF795gpC (7 pmol per well) and 100 μl of sera previously diluted in PBS at 1:500 was added to each well. Different types of anti-human secondary antibodies were used at optimal dilutions (anti-IgG, 1:2000 from Pierce, Rockford, IL; anti-IgG1, 1:500; anti-IgG2, 1:2000; anti-IgG3, 1:1000; anti-IgG4, 1:2000; anti-IgM, 1:2000; anti-IgA, 1:1000, and anti-IgE,1:500 from Southern Biotechnology Associates, Inc., Birmingham, AL). The ELISA reaction was developed with 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) from Sigma (St. Louis, MO) and antibody binding measured at 405 nm. The determinations were performed in a minimum of 14 sera samples from all the cohorts. When the numerical study required more data for significance analysis, the determination of antibody composition was extended to a bigger number of samples. All the experiments were performed in triplicate.
Statistical analysis
Correlation between the activation levels of NF795gpC promoted by each sera sample and titers of the different types of Igs found in the same sera were done using the linear regression analysis tool from SigmaPlot version 10.0. The comparisons between activation levels in sera sets according to Ig titer and group of treatment were performed by the Kruskal-Wallis nonparametric statistical test. P values of less than 0.05 were considered as statistically significant.
RESULTS AND DISCUSSION
To determine the possible impact of the ART in the humoral response against HIV-1, we determined which specific antibody populations are responsible for the sera-mediated NF795gpC activation in both nontreated and ART-treated HIV-1-infected individuals. For that we explored, in a selected set of sera samples (Table 1) , the correlation between the seramediated activation of NF795gpC (by the increase in the β-galactosidase activity) and the prevalence of different classes of antibodies (by immunoreactivity with the P1 B-cell epitope of HIV-1 displayed by NF795gpC). The profiles of biosensor signals induced by sera ( Fig. 1 ) were indistinguishable when comparing sera from ART patients and sera from nontreated patients, as confirmed by a Kruskal-Wallis test (H = 3.37, p = 0.06). Negative controls, namely 8 sera from noninfected individuals, showed no sensor activation as expected (not shown). When investigating possible linear dependence between activation factors and the amount of specific antibody subpopulations, we found that, as described previously, the levels of allosteric activation of NF795gpC correlated significantly (P = 0.025) with the prevalence of anti-HIV-1 IgG4 in sera (Table 2 and Fig. 2B) . This result indicates a main contribution of such IgG subclass in sensor activation. However, when analyzing exclusively the sera set from nontreated individuals, the dependence between the sensor activation signals and IgG4 titers was not observed. Instead, in absence of antiviral treatment, the occurrence of specific anti-gp41 IgM antibodies clearly determined the extent of NF795gpC activation (P = 0.005; Fig. 2A ).
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FIG. 1.
Distribution of patient frequency regarding sensor activation levels promoted by individual patient sera (increase of enzymatic activity, as %). Patient frequency was calculated by referring the number of patient sera in each group of activation to the total number of patient sera within the group of treatment (total patients, treated and nontreated patients). White bars represent the total number of patients, right-dashed bars the nontreated patients, and rhombus-filled bars the total of patients who had followed an antiretroviral therapy. Because the composition of the ART was nonhomogeneous ( Table 1) , the shift in the contribution of specific immunoglobulin populations to the sensor activation could not be attributed to any specific drug. In addition, ART intervals were also diverse in the set of analyzed individuals. In those in which the treatment had been interrupted, viral load values were notably high, indicating the recovery of viral replication after interruption ( Table 1) . Because both sera populations (from patients receiving interrupted ART and continuous treatment) were statistically indistinguishable regarding sensor activation (P = 0.48; not shown), the changes in the functionality of the antiviral response caused by ART are not reverted by a late recovery of virus multiplication, and are, therefore, irreversible. In summary, in naïve HIV-1-infected individuals, IgM is the antibody class most efficiently modifying the immunodominant B-cell epitope of gp41, but in individuals receiving ART there is a clear functional dominance of IgG4. Such effect is irrespective of both the specific drugs used in ART and the continuity of the treatment, and therefore, it does not depend on low viral replication or load. Therefore, the drop of antigenemia generally associated with ART is probably causing a functional adaptation of the humoral response in which IgG4 gains neutralization competence at the expense of IgM.
Importantly, the results shown here stress the value of allosteric nanosensors as powerful tools for functional and dynamic screening of individual anti-HIV immune responses, beyond their utility as mere diagnostic tools.
